Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell.

Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source.

Emerging from the Institut Pasteur, nurtured by Argobio, and honored with Pfizer x BioLabs’ Golden Ticket, Enodia is built on breakthrough science with a singular mission: unveiling the translocon to unlock innovative therapies.

Read our press release.